Wolverine Peptide side effects.

Wolverine Stack side effects

Nausea, dizziness and skin or gum darkening have been documented during BPC-157/TB-500 exposure. Local reactions also occur in related injectable-peptide reports. The available records do not establish how often each occurs. [1] [2]

Headache and tiredness also appear in a physician's Wolverine Stack counseling information. That page supplies no event counts, so these symptoms cannot be ranked by frequency. [3]

Nausea and dizziness

Severe dizziness started on day three in a firsthand combination account and lasted at least another 24 hours. The regimen included BPC-157 twice daily and one TB-500 administration. The author skipped subsequent amounts but remained nauseated and dizzy. The account does not isolate the responsible ingredient. [2]

Adding food, drinking coffee or changing the timing does not identify why a reaction happened. Contact a clinician before taking more if symptoms are significant or recurring; bring the exact ingredient amounts and the timing of every product used.

Skin and gum darkening

FDA reviewed a BPC-157/TB-500 case in which widespread skin and gum darkening began after one week. The same reaction returned after the product was restarted two weeks later. No further reactions were reported after it was discontinued. [1]

New pigmentation warrants a medical assessment. Do not restart a suspect product simply to test whether the color change returns. A photograph and the batch label can help the clinician compare the change and identify the exposure.

Injection-site irritation and infection

Spreading redness, increasing warmth, swelling and pain need prompt assessment. Fever, chills, pus or red streaks add concern for infection. Bacteria can enter through a break in the skin. [5]

A pen still uses a needle. Use a fresh needle and syringe when applicable, keep preparation clean and never share injection equipment between people. [7]

Urgent reactions

Seek help immediately rather than waiting to see whether a smaller amount feels different. A serious allergy can involve the peptide, another ingredient or the finished formulation.

Allergies and immune reactions

An injected peptide can trigger an immune response. FDA flags this concern for BPC-157, including the possible effects of peptide impurities and clumping. This is a safety concern, not a measured allergy rate for Wolverine Stack. [15]

Hives or a new rash can signal allergy; nausea or dizziness alone cannot identify one. Breathing difficulty or throat swelling needs the emergency response above. [13]

Vial and pen: different points to check

Wolverine Stack product specifications and redacted COA → [14]

The COA's safety tests

The supplied in-house powder-lot report records 99.65% combined HPLC area purity, 0.12 EU/mg endotoxin and no growth in its sterility test. It identifies both peptides by LC-MS. These results cover the sampled powder lot PL-2609-011. [9]

HPLC area purity is separate from an exact fill-content assay. A high purity number also cannot rule out an allergy.

Long-term use and cancer concerns

Short courses in small studies cannot establish long-term Wolverine Stack safety. A two-person BPC-157 IV pilot recorded no adverse effects, and a separate 40-person thymosin beta-4 IV study found no serious adverse events. Neither tested repeated subcutaneous use of this blend. [10] [11]

Cancer concerns involve repair signaling and blood-vessel growth. In an experiment that made mouse melanoma cells produce extra thymosin beta-4, cell movement and tumor blood-vessel formation increased. That experiment does not measure cancer risk from a Wolverine Stack injection in humans. [12]

Existing cancer, cancer treatment, pregnancy or breastfeeding calls for individual medical review before exposure. No blend study cited here establishes safety in those situations. A negative side-effect experience is also a reason to review the product, not automatically lengthen the break and restart.

Blood pressure and blood clots

Have blood thinners, aspirin and blood-pressure medicines included in a medication review before adding the blend. A missing interaction warning is not evidence that the combination was tested. [13]

Women, pregnancy and breastfeeding

The available Wolverine Stack reports do not establish different side-effect rates for men and women. The skin-and-gum reaction involved a woman, but one case cannot show that women are more likely to develop it. [1]

A 2021 trial of recombinant thymosin beta-4 included men and women; pregnancy and breastfeeding were outside its studied population. It tested that ingredient intravenously, not the Wolverine Stack blend. [16]

Do not self-start Wolverine Stack during pregnancy or breastfeeding. If you are trying to conceive or have already used it during pregnancy, discuss the exposure and exact product with your obstetric clinician. The short ingredient studies do not establish safety for a developing baby. [1] [16]

Overlapping peptides and medicines

Wolverine Stack already contains BPC-157 and TB-500. Adding a separate BPC-157 or TB-500 product raises that ingredient's total. For example, 1 mg of a 1:1 blend plus 500 mcg separate BPC-157 gives 1,000 mcg BPC-157 and 500 mcg TB-500.

Show the complete product and medicine list to the treating clinician or pharmacist when a new symptom appears. Include pain relievers, supplements and anything started or changed recently. Drug interactions can involve medicines, supplements, food and existing conditions. [13] Check blend and ingredient totals →

FDA approval and the 2026 compounding review

BPC-157 has no FDA-approved human drug product. Mixing it with TB-500 and calling it Wolverine Stack does not confer drug approval. [1]

The July 23, 2026 FDA committee agenda covered BPC-157 and TB-500-related substances for the 503A compounding list. Its recommendations are advisory. Compounding eligibility and approval of a finished medicine are different decisions; compounded drugs themselves are not FDA-approved. [17] [18]

US regulatory references checked 5 November 2026.

WADA, NCAA and drug tests

Do not assume BPC-157 is undetectable. Laboratory methods can identify it and selected metabolites in human urine. That research does not establish a reliable human detection window or a safe stop date before competition. [22]

Competitive athletes should check the complete blend with their team's medical staff and anti-doping authority before use. [20]